Syndax Pharmaceuticals【SNDX】銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

14.23

買値

13.48

売値

14.75

出来高

2,111,744

14.20 日の範囲 15.16

13.8511 52 週間の範囲 25.34

時価総額

1.215B

前日終値

14.94

始値

15.13

時刻

981

14.23

(priorref)

最終取引時間

06:01:57

財務取引量

US$ 30,611,288

VWAP

14.4957

平均取引量 (3 か月)

1,490,899

発行済株式数

85,357,675

配当利回り

PER

-5.89

1 株当たり利益 (EPS)

-2.45

歳入

純利益

-209.36M

Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and ... Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.syndax.com

本社

Wilmington, Delaware, USA

設立

Syndax Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker SNDX. The last closing price for Syndax Pharmaceuticals was US$14.94. Over the last year, Syndax Pharmaceuticals shares have traded in a share price range of US$ 13.8511 to US$ 25.34.

Syndax Pharmaceuticals currently has 85,357,675 shares in issue. The market capitalisation of Syndax Pharmaceuticals is US$1.28 billion. Syndax Pharmaceuticals has a price to earnings ratio (PE ratio) of -5.89.

全体の流れ

ブルリッシュ

ネットプレミアム

25k

Calls / Puts

100.00%

買い / 売り

100.00%

OTM / ITM

100.00%

Sweeps比率

0.00%

Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial

Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial PR Newswire WALTHAM, Mass...

Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting

Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting PR Newswire WALTHAM...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass., Dec. 3, 2024 WALTHAM, Mass., Dec. 3, 2024 /PRNewswire/ -- Syndax Pharmaceuticals...

Syndax Announces Participation at the Citi 2024 Global Healthcare Conference

Syndax Announces Participation at the Citi 2024 Global Healthcare Conference PR Newswire WALTHAM, Mass., Nov. 27, 2024 WALTHAM, Mass., Nov. 27, 2024 /PRNewswire/ -- Syndax Pharmaceuticals...

Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A...

Form 8-K - Current report

Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib

Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib PR Newswire WALTHAM, Mass., Nov. 12, 2024 – Primary endpoint...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-2.57	-15.2976190476	16.8	17.28	13.8511	1929739	15.93094218	CS
4	-1.89	-11.7245657568	16.12	17.87	13.8511	2150820	16.1225203	CS
12	-3.84	-21.2506917543	18.07	22.5	13.8511	1490899	17.51495561	CS
26	-5.23	-26.8756423433	19.46	25.07	13.8511	1241191	18.92661305	CS
52	-3.41	-19.3310657596	17.64	25.34	13.8511	1258042	20.12329597	CS
156	-2.23	-13.5479951397	16.46	29.86	11.215	1001375	19.54892623	CS
260	5.57	64.3187066975	8.66	29.86	6.32	825005	19.14741141	CS

銘柄コード	株価	出来高
JZXNJiuzi Holdings Inc	US$ 2.32 (29.46%)	492.06k
SGRPSpar Group Inc	US$ 2.25 (20.97%)	500.08k
BHATBlue Hat Interactive Entertainment Technology	US$ 0.1317 (11.99%)	2.15k
TZUPThumzup Media Corporation	US$ 4.49 (9.51%)	1.86k
LAESSEALSQ Corporation	US$ 1.24 (8.71%)	1.57M
SFHGSamfine Creation Holdings Group Ltd	US$ 2.76 (-9.21%)	145.77k
SMSISmith Micro Software Inc	US$ 0.745 (-6.76%)	3.24k
XCHXCHG Ltd	US$ 24.00 (-6.47%)	750
OCXOncocyte Corporation	US$ 2.29 (-6.15%)	1,000
HYFMHydrofarm Holdings Group Inc	US$ 0.6553 (-5.94%)	110
ESGEiShares Inc iShares ESG Aware MSCI EM ETF	US$ 35.1115 (-0.39%)	2.06M
LAESSEALSQ Corporation	US$ 1.24 (8.71%)	1.57M
TLTiShares 20 plus Year Treasury Bond	US$ 92.1701 (-0.01%)	962.9k
QQQInvesco QQQ Trust Series 1	US$ 529.30 (-0.12%)	865.92k
IGOViShares International Treasury Bond	US$ 39.761 (0.10%)	844.93k

銘柄コード

株価

出来高